Canopy Growth (NASDAQ:CGC) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Canopy Growth (NASDAQ:CGC) from a sell rating to a hold rating in a report released on Saturday.

Separately, Weiss Ratings upgraded Canopy Growth from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Canopy Growth Stock Up 4.1%

Shares of CGC opened at $0.97 on Friday. The stock’s 50-day moving average price is $0.96 and its two-hundred day moving average price is $1.04. Canopy Growth has a 12 month low of $0.84 and a 12 month high of $2.38. The company has a market capitalization of $435.01 million, a PE ratio of -2.16 and a beta of 0.81. The company has a current ratio of 3.34, a quick ratio of 2.64 and a debt-to-equity ratio of 0.31.

Canopy Growth (NASDAQ:CGC) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.02. Canopy Growth had a negative return on equity of 26.95% and a negative net margin of 75.27%.The company had revenue of $142.62 million during the quarter, compared to analysts’ expectations of $58.21 million. On average, analysts anticipate that Canopy Growth will post -0.11 EPS for the current year.

Insider Transactions at Canopy Growth

In other Canopy Growth news, insider Christelle Gedeon sold 58,994 shares of the stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $0.97, for a total transaction of $57,224.18. Following the completion of the sale, the insider directly owned 705,506 shares in the company, valued at approximately $684,340.82. This trade represents a 7.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Luc Mongeau sold 135,231 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $0.97, for a total value of $131,174.07. Following the sale, the chief executive officer owned 1,723,913 shares in the company, valued at approximately $1,672,195.61. The trade was a 7.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 224,958 shares of company stock valued at $217,137. Company insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Canopy Growth

A number of institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Securities LLC increased its stake in shares of Canopy Growth by 4.4% in the 2nd quarter. Two Sigma Securities LLC now owns 280,852 shares of the company’s stock valued at $343,000 after acquiring an additional 11,942 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in Canopy Growth by 23.1% during the fourth quarter. Commonwealth Equity Services LLC now owns 73,739 shares of the company’s stock worth $84,000 after acquiring an additional 13,814 shares in the last quarter. Boothbay Fund Management LLC bought a new position in Canopy Growth during the second quarter worth $30,000. Octavia Wealth Advisors LLC acquired a new stake in Canopy Growth in the fourth quarter worth $30,000. Finally, Mackenzie Financial Corp grew its holdings in Canopy Growth by 33.1% in the third quarter. Mackenzie Financial Corp now owns 111,945 shares of the company’s stock worth $163,000 after purchasing an additional 27,823 shares during the period. 3.33% of the stock is currently owned by institutional investors.

Trending Headlines about Canopy Growth

Here are the key news stories impacting Canopy Growth this week:

• Positive Sentiment: Net revenue increased 13% year over year to C$81.2 million, exceeding the approximately C$58.9 million analyst consensus. Growth came from all major businesses: Canada medical cannabis rose 22%, Canada adult-use cannabis 10%, international cannabis 10% and Storz & Bickel 6%. Canopy Growth Reports First Quarter Fiscal Year 2027 Financial Results
• Positive Sentiment: Adjusted gross margin improved to 31% from 25% a year earlier, while the adjusted EBITDA loss narrowed 59% year over year. The margin improvement supports the company’s turnaround strategy and helped drive the stock higher. Canopy Growth reports fiscal first quarter revenue growth, improved margins
• Positive Sentiment: Canopy Growth reported a quarterly loss of C$0.02 per share, better than the expected C$0.04 loss and substantially improved from a C$0.14 loss in the prior-year quarter. This represented a 50% earnings surprise. Canopy Growth Corporation Reports Q1 Loss, Tops Revenue Estimates
• Neutral Sentiment: The company remains unprofitable, with a negative net margin and negative return on equity. Investors will likely focus on whether revenue momentum and cost controls can eventually produce positive EBITDA and sustainable earnings.
• Negative Sentiment: A proposed partial settlement in a securities class-action lawsuit would resolve claims against former auditor KPMG if approved, but the case would continue against Canopy Growth and other defendants, leaving a potential legal overhang. Certification and Hearing to Approve Proposed Partial Settlement

Canopy Growth Company Profile

Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.

The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments.